The Future of Urological Disorders Therapeutics to 2016

Aug. 2, 2010 - PRLog -- GBI Research’s report, “The Future of Urological Disorders Therapeutics to 2016 - Increasing awareness and aging population will drive Benign Prostatic Hyperplasia and Urinary Incontinence Markets”, provides in-depth analysis of unmet needs, drivers and barriers that impact the global urological disorders market. The report analyzes the markets for urological disorders in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, prices and volumes are forecast until 2016 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

Claim your free sample pages here  http://www.globalmarketsdirect.com/SamplePdfRequest.aspx?...

Scope

   * The scope of this report includes:
   * Annualized market data for the urological disorders market from 2001 to 2009, forecast forward to 2016.
   * Analysis of the leading therapeutic segments, including urinary incontinence, benign prostatic hyperplasia and urinary tract infections.
   * Analysis of the urological disorders market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain and Japan.
   * Market characterization of the urological disorders market, including market size, annual cost of therapy, sales volume and treatment usage patterns.
   * Key drivers and barriers that have a significant impact on the market.
   * Coverage of pipeline molecules in various phases of drug development.
   * Competitive benchmarking of leading companies. The key companies studied in this report are Allergen Inc, Astellas Pharma, Pfizer Inc, Cubist pharmaceuticals Inc, Novexel SA, Osel Inc, Eli Lilly and Company, Nippon Shinyaku Co. Lt and Protox Therapeutics, Inc.
   * Key M&A activities, licensing agreements, that have taken place in 2009 in the global urological disorders market.

Reasons to Buy

   * The report will enhance your decision making capability. It will allow you to
   * Align your product portfolio to the markets with high growth potential.
   * Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.
   * Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with more efficiency and better safety.
   * Develop key strategic initiatives by understanding the key focus areas of leading companies.
   * Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps.

Follow us on twitter for all the latest news and reports http://twitter.com/Medical_RVs

# # #

Global Markets Direct is a global market intelligence services company providing information research and analysis products and services.